Ikena Oncology Inc

NASDAQ:IKNA 4:00:00 PM EDT

1.29

-0.06 (-4.44%)

7:09:26 PM EDT: $1.33 +0.04 (+3.10%)

Market Cap (Intraday)	62.26M
Current PE	N/A
Forward PE	N/A
2yr Forward PE	N/A

See more stats

Estimates Current Quarter

Revenue	$1.75 Million
Adjusted EPS	-$0.40

See more estimates

10-Day MA	$1.31
50-Day MA	$1.40
200-Day MA	$2.86

See more pivots

Ikena Oncology Inc Stock, NASDAQ:IKNA

645 Summer Street, Suite 101, Boston, Massachusetts 02210

United States of America

Phone: +1.857.273.8343

Number of Employees: 43

http://www.ikenaoncology.com

Description

Ikena Oncology, Inc. is a clinical stage biotechnology company, which engages in the development of patient directed and biomarker driven therapies for cancer patients. Its product pipeline includes IK-930, RAS Signaling, IK-175, IK-412, and IK-007. The company was founded by Mark Manfredi and George Georgiou in February 2016 and is headquartered in Boston, MA.